Literature DB >> 9072045

Biochemistry, regulation and potential function of kallistatin.

J Chao1, L Chao.   

Abstract

Components of the tissue kallikrein-kinin system include tissue kallikrein, kallistatin (kallikrein-binding protein), kininogen, kinin, bradykinin B1 and B2 receptors, and kininases. Tissue kallikrein is a serine proteinase which is capable of cleaving kininogen substrate to release the vasoactive kinin peptide. The binding of kinin to its specific receptor at target organs can produce a wide spectrum of biological effects. Kinin generation is primarily determined by the activity and availability of kallikrein since the level of kininogen is not a rate-limiting factor. Kallikrein levels are controlled by its rate of synthesis, activation, inactivation and clearance. The synthesis of tissue kallikrein is regulated transcriptionally, and its activity is regulated through post-translational processing and inactivation by inhibitors. Kallistatin is a newly discovered serine proteinase inhibitor (serpin) which forms a specific and covalently-linked complex with tissue kallikrein. Kallistatin may regulate tissue kallikrein's activity, bioavailability and clearance rate at the post-translational level. The major site of kallistatin synthesis is the liver with lower expression levels in the pancreas and kidney. Unlike many other serpins which are only present in the plasma, kallistatin is found in various tissues, cells and bodily fluids. The fact that both tissue kallikrein and kallistatin are widely distributed in tissues suggests kallistatin's role as a potential regulator of kallikrein outside the circulation. Protein purification and molecular cloning techniques have been used to study the structure, regulation and function of the components of the kallikrein-kinin system and for exploring their roles in ion transport, inflammation and blood pressure regulation. Considerable progress has been made in recent years to achieve these goals. This article provides an overview of the biochemical properties and potential physiological and pathophysiological roles of kallistatin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9072045

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  23 in total

1.  Tissue-specific expression and promoter analyses of the human tissue kallikrein gene in transgenic mice.

Authors:  W Xiong; J Wang; L Chao; J Chao
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Attenuation of persistent experimental pancreatitis pain by a bradykinin b2 receptor antagonist.

Authors:  Qingmin Chen; Louis P Vera-Portocarrero; Michael H Ossipov; Marina Vardanyan; Josephine Lai; Frank Porreca
Journal:  Pancreas       Date:  2010-11       Impact factor: 3.327

3.  Kallikrein binding protein (KBP) maps to rat chromosome 6 but does not cosegregate with blood pressure in a GH x BN cross.

Authors:  A Chen; M R Grigor; C M Thompson; E L Harris
Journal:  Mamm Genome       Date:  1997-09       Impact factor: 2.957

Review 4.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

5.  Kallistatin is a potent new vasodilator.

Authors:  J Chao; J N Stallone; Y M Liang; L M Chen; D Z Wang; L Chao
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

6.  Kallistatin inhibits TGF-β-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression.

Authors:  Youming Guo; Pengfei Li; Grant Bledsoe; Zhi-Rong Yang; Lee Chao; Julie Chao
Journal:  Exp Cell Res       Date:  2015-07-05       Impact factor: 3.905

Review 7.  Kallistatin suppresses cancer development by multi-factorial actions.

Authors:  Julie Chao; Pengfei Li; Lee Chao
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-14       Impact factor: 6.312

8.  Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress.

Authors:  Bo Shen; Lee Chao; Julie Chao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

9.  Increased serum kallistatin levels in type 1 diabetes patients with vascular complications.

Authors:  Alicia J Jenkins; Jeffrey D McBride; Andrzej S Januszewski; Connie S Karschimkus; Bin Zhang; David N O'Neal; Craig L Nelson; Jasmine S Chung; C Alex Harper; Timothy J Lyons; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-09-22

10.  Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formation.

Authors:  Thomas Griesbacher; Irmgard Rainer; Beate Tiran; Edwin Fink; Fred Lembeck; Bernhard A Peskar
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.